5/16/2013
Neuroscience Seminar Series
Anna Devor, Ph.D., is an Associate Adjunct Professor in the departments of Neurosciences and Radiology at UCSD and is PI on R01 and R21 grants from NINDS and NIBIB. She also holds an appointment as instructor in radiology in the Martinos Center for Biomedical Imaging at Massachusetts General Hospital. Dr. Devor is an expert in neuro-vasuclar-metabolic coupling and regulation of cerebral blood flow.
Dr. Devor is known for her innovative application of optical imaging techniques for in vivo imaging of brain activity. She has published extensively in imaging and recording in vivo in rats and mice using 2-photon microscopy, calcium-sensitive dye imaging, voltage-sensitive dye imaging, intrinsic imaging of blood flow and oxygenation and intra/extracellular electrophysiological recordings.
The overall goals of her research are to combine direct and quantitative measurement of hemodynamic and neuronal parameters simultaneously with fMRI aiming to understand the relationship between the BOLD response and the underlying neuroglial activity. This includes establishing microscopic correlates of large-scale (populational) hemodynamic and neuroglial signals with a focus on the integration of macro- and microscopic imaging measurements.
For more information go to
http://neuroseries.info.nih.govAir date: 5/20/2013 12:00:00 PM
5/15/2013
June 3rd AIDS Research Advisory Committee Meeting
Air date: 6/3/2013 1:00:00 PM
5/14/2013
Dr. Anthony S. Fauci will address the full council. Dr. John Mascola will also present to the full council.
Air date: 6/3/2013 10:30:00 AM
5/14/2013
CC Grand Rounds: (1) Inflammation in Epilepsy: A New Pathophysiologic Mechanism? (2)PET Imaging of P-gp: An Efflux Transporter that Protects the Brain but Also Causes Drug Resistance
For more information go to
http://www.cc.nih.gov/about/news/grcurrent.htmlAir date: 5/29/2013 12:00:00 PM
5/14/2013
Pre-market testing of drugs produces reasonably high quality information about the efficacy of the drug as a treatment for the condition for which it was approved, but gives a very incomplete picture of the drug’s safety. It is only after a drug is marketed and used on a more widespread basis over longer periods of time that it is possible to identify other effects, such as rare but serious adverse effects, or those that are more common in the special subgroups excluded from the trial, among others. Post-marketing surveillance currently relies on voluntary reporting to the FDA by health care professionals (and recently, patients themselves). Self-reported patient information captures a valuable perspective not captured by other means, and has been found to be of similar quality to that provided by health professionals. However, the value of numerous, informal self-reports such as those found in social network postings has not been evaluated. Through recently awarded NIH/NLM funding, Dr. Gonzalez is deploying the infrastructure needed to explore the value of such postings as a source of “signals” of potential adverse drug reactions soon after the drugs hit the market. Despite the significant challenge of processing colloquial text, her studies showed promising results. Additional evaluation on un-annotated comments revealed encouraging correlations between adverse drug reactions found by her system and the documented reactions for those drugs. An overview of the methods and ongoing findings of this project wil be discussed in this presentation, particularly as Dr. Gonzalez seek to answer the question: can social media provide reliable signals of adverse drug reactions?
Dr. Gonzalez is an assistant professor at the Department of Biomedical Informatics (BMI) at Arizona State University, and data core director of one of the National Institute on Aging supported Alzheimer's Disease Centers. She is a member of the National Library of Medicine's chartered scientific review committee - the Biomedical Library and Informatics Research Committee. She leads the Discovery through Integration and Extraction of Genomic knOwledge (DIEGO) lab, in the area of knowledge discovery, focusing her research on translational applications of information extraction using natural language processing techniques. Work in the DIEGO lab spans the spectrum from data extraction (concepts and relationships) to data integration, modeling and advanced analysis to facilitate biomedical discovery. From transcription factor binding site pattern discovery, through gene prioritization for drug and disease-related studies, to patient cohort management and adverse drug reaction surveillance, the lab has contributed to the advancement of knowledge discovery methods across the biomedical spectrum.
Air date: 6/5/2013 2:00:00 PM
5/14/2013
The Fifth Annual CMS Multi-State Medicaid HITECH Conference will be held May 21-23, 2013.
For more information go to
http://www.medicaidhitechconference.comAir date: 5/22/2013 8:00:00 AM
4/30/2013
National Advisory Mental Health Council Open Policy Session
Air date: 5/30/2013 8:30:00 AM
